Biologics: Targets and Therapy
Volume 6, 2012 - Issue
Open access
79
Views
11
CrossRef citations to date
0
Altmetric
Review
First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
Kim-Son H NguyenStanford Cancer Institute, Stanford University, Stanford, CA, USA
& Joel W NealStanford Cancer Institute, Stanford University, Stanford, CA, USACorrespondence[email protected]
Pages 337-345
|
Published online: 25 Sep 2012
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.